Update on Cleared US FDA IND for Acute Ischemic Stroke Using Neural Stem Cell Derived EVs
Time: 11:00 am
day: Conference Day One
Details:
- AB126: A first-in-class EV Therapy for stroke and CNS diseases and designed to treat stroke patients with poor prognosis post-reperfusion: A high medical-need
- IND-cleared, with preliminary work underway for the first-in-human trial
- AB126 offers a novel, multi-target solution with a clear mechanisms or action that address inflammation, immune response and repair
NEW DATA!
